Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma

Yosuke Matsumoto¹, Hisao Nagoshi², Mihoko Yoshida¹, Seiichi Kato³, Junya Kuroda³, Kazuho Shimura¹, Hiroto Kaneko¹, Shigeo Horiike², Shigeo Nakamura³ and Masafumi Taniwaki¹,⁴

Abstract:
Objective It has been postulated that the normal counterpart of angioimmunoblastic T-cell lymphoma (AITL) is the follicular helper T-cell (TFH). Recent immunological studies have identified several transcription factors responsible for T-cell differentiation. The master regulators associated with T-cell, helper T-cell (Th), and TFH differentiation are reportedly BCL11B, Th-POK, and BCL6, respectively. We explored the postulated normal counterpart of AITL with respect to the expression of the master regulators of T-cell differentiation.

Methods We performed an immunohistochemical analysis in 15 AITL patients to determine the expression of the master regulators and several surface markers associated with T-cell differentiation.

Results BCL11B was detected in 10 patients (67%), and the surface marker of T-cells (CD3) was detected in all patients. Only 2 patients (13%) expressed the marker of naïve T-cells (CD45RA), but all patients expressed the marker of effector T-cells (CD45RO). Nine patients expressed Th-POK (60%), and 7 (47%) expressed a set of surface antigens of Th (CD4-positive and CD8-negative). In addition, BCL6 and the surface markers of TFH (CXCL13, PD-1, and SAP) were detected in 11 (73%), 8 (53%), 14 (93%), and all patients, respectively. Th-POK-positive/BCL6-negative patients showed a significantly shorter overall survival (OS) than the other patients (median OS: 33.0 months vs. 74.0 months, p=0.020; log-rank test).

Conclusion Many of the AITL patients analyzed in this study expressed the master regulators of T-cell differentiation. The clarification of the diagnostic significance and pathophysiology based on the expression of these master regulators in AITL is expected in the future.

Key words: angioimmunoblastic T-cell lymphoma, follicular helper T-cell, BCL11B, Th-POK, BCL6

(Intern Med 56: 2851-2856, 2017)
(DOI: 10.2169/internalmedicine.8570-16)

Introduction

Angioimmunoblastic T-cell lymphoma (AITL) is a T-cell lymphoma composed of clusters of atypical medium-sized or large neoplastic lymphocytes with clear-to-pale cytoplasm and the infiltration of reactive lymphocytes, eosinophils, plasma cells, histiocytes and follicular dendritic cells (1).

During T-cell maturation, naïve T cells comprise two distinct cell types: CD4-positive and CD8-negative helper T cells (Th), and CD4-negative and CD8-positive cytotoxic T cells. Following antigen stimulation, naïve Th cells differen-
The neoplastic cells of AITL are thought to originate into several subtypes of effector Th cells: Th type 1 (Th1), Th type 2 (Th2), follicular helper T cells (TFH), regulatory T cells (Treg), interleukin-17-producing T cells (Th17), central memory T cells, and effector memory T cells (2).

Previously, these subtypes of effector Th cells were classified according to their pattern of cytokine secretion and expression of surface antigens, including chemokine receptors. Recent immunologic studies, however, have identified several transcription factors responsible for T-cell differentiation. The master regulators associated with T-cell, Th, Th1, Th2, TFH, Treg, and Th17 differentiation are reportedly BCL11B, Th-POK, and BCL6. Furthermore, we immunohistochemically analyzed the expression of BCL11B, Th-POK, and BCL6-positive, Th-POK (5), T-Bet (6), GATA3 (7), BCL6 (8, 9), FOXP3 (10), and RORγt (11), respectively.

The detection of the expression of these master regulators has contributed to the identification of the normal counterparts of some histological subtypes of T-cell lymphoma. For example, the normal counterpart of some adult T-cell leukemia patients was reported to be Treg because of the detection of FOXP3 expression (12). In addition, we previously reported the postulated that the normal counterparts of 10 peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) patients were Th1 (T-BET-positive), Th2 (GATA3-positive), TCM (CCR7- and CD62L-positive), and TFH (BCL6-positive) (13).

The neoplastic cells of AITL are thought to originate from effector Th cells because these tumor cells express surface antigens such as pan-T-cell (CD3), effector-T-cell (CD45RO) (14), and Th (CD4) markers. Regarding the subtypes of effector Th cells, several immunohistochemical studies (15-18) have shown that the neoplastic cells of AITL express the transcriptional factors and surface antigens associated with TFH, such as BCL6, CXCL13, PD-1, and SAP. A gene expression profile analysis also demonstrated a molecular link between AITL and TFH cells (19, 20). These results indicate that the neoplastic cells of AITL are derived from TFH cells.

In this study, to identify the postulated normal counterpart of AITL with respect to the master regulators of T-cell differentiation, we immunohistochemically analyzed the expression of BCL11B, Th-POK, and BCL6. Furthermore, we compared the results with those for previously known markers of these cells in AITL patients.

### Materials and Methods

**Patients**

The study population comprised 15 Japanese patients with histopathologically diagnosed AITL at the hospital of Kyoto Prefectural University of Medicine and Kyoto Minami Hospital between 1990 and 2012. These patients were 4 men and 11 women who ranged in age from 38 to 85 years (Table 1, Figure A). The clinical data of patients No. 1-4, 6, and 9-15 were previously reported (21). Ten patients (No. 2, 4, 6, 8-13, 15) were treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen as first-line therapy. Two patients received stem cell transplantation.

| Patient | Age/Sex | Biopsy location | TCR Cβ1 rearrangement | Representative karyotype | EBER-ISH |
|---------|---------|-----------------|----------------------|--------------------------|---------|
| 1       | 61/M    | Lymph node     | ND                   | 46.XY                    | +       |
| 2       | 68/F    | Lymph node     | TCR Cβ1: t(1:14)(q21;q32.3) | 3/21                  | +       |
| 3       | 65/F    | Lymph node     | +                    | 46.XX                    | -       |
| 4       | 57/F    | Subcutaneous nodule | +                    | 47.XX,+3 (6/8) | -       |
| 5       | 85/F    | Lymph node     | ND                   | 46.XX                    | -       |
| 6       | 68/F    | Skin/Lymph node | (PB)                 | 46.XX,del(9)(q?),add(14)(q32) [1/20] | -       |
| 7       | 81/F    | Lymph node     | ND                   | 46.XX                    | +       |
| 8       | 70/M    | Lymph node     | NE                   | 47.XY,add(4)(q21),del(5)(q?),+add(6)(p11),del13(q?),add(15)(p11),add(19)(q13) [2/20] | +       |
| 9       | 38/M    | Lymph node     | ND                   | 46.XY,add(1)(p11),add(4)(p11),add(8)(q24),del(9)(q?),11,add(14)(q32),15,add(18)(q21),add(19)(p13),add(21)(q22),-22,-22,+4mar [2] | -       |
| 10      | 68/M    | Lymph node     | +                    | No metaphase             | -       |
| 11      | 64/F    | Lymph node     | ND                   | 47.XX,add(1)(q21),del(2)(q?),+der(7)(1;7)(q12;q32),add(10)(p11.2),add(13)(p11.2) [1/15] | -       |
| 12      | 75/F    | Lymph node     | ND                   | 46.XX                    | -       |
| 13      | 63/F    | Skin           | ND                   | -                        | -       |
| 14      | 83/F    | Lymph node     | ND                   | 46.XX,inv(9)(p24q21) [1/20] | -       |
| 15      | 68/F    | Lymph node     | ND                   | No metaphase             | -       |

ND: no data, NE: not evaluable, PB: peripheral blood, EBER-ISH: Epstein-Barr virus-encoded RNA in situ hybridization
Autologous and reduced-intensity allogeneic peripheral blood stem cell transplantations (PBSCTs) were performed in Patient 4, and autologous PBSCT and myeloablative cord blood transplantation were performed in Patient 9.

Informed consent was obtained from each patient in accordance with institutional guidelines. Each patient enrolled in the study was reviewed by two pathologists for confirmation of AITL. The histopathologic diagnosis was in accordance with the World Health Organization Classification of Neoplastic Disorders of the Lymphoid Tissues (1).

**Methods**

We subjected 4-μm-thick paraffin-embedded sections of diagnostic lymph node or skin biopsy specimens to immunohistochemical staining using a standard indirect avidin-biotin peroxidase method and diaminobenzidine (DAB) color development (DAKO Envision™, Carpinteria, USA). In line with previously reported studies, the patients were considered positive if ≥20% of the tumor cells were stained with an antibody (16, 17). Paraffin-embedded lymph nodes with a histological diagnosis of nonspecific lymphadenitis and diffuse large B-cell lymphoma were used as negative and positive staining controls.

Primary antibodies against the following transcription factors were introduced: BCL11B (dilution 1: 100; Novus Biologicals, Littleton, USA), Th-POK (dilution 1:50; Abgent, San Diego, USA), and BCL6 (PG-B6p, dilution 1: 15; DAKO). Primary antibodies against the following surface antigens and chemokine were used: CD3 in clinical use, CD4 (4B12, dilution 1:70; DAKO), CD8 (C8/144B, no dilution; DAKO), CD45RA (4KB5, dilution 1: 70; DAKO), CD45RO (UCHL-1, dilution 1:70; DAKO), CXCL13 (dilution 15 μg/mL; R&D Systems), PD-1 (dilution 15 μg/mL; R&D Systems) and SAP (SH2D1A, dilution 1: 250; Santa Cruz Biotechnology, Santa Cruz, USA). All antibodies were treated and used in accordance with the manufacturers’ instructions.

We analyzed the relationship between the expression of the master regulators and the immunohistochemical and clinical features listed in Tables 2 and 3 using Fisher’s exact test. The overall survival (OS) distributions were calculated with the Kaplan-Meier method and compared by the log-rank test.

**Table 2. Clinical Characteristics of the 15 Patients with Angioimmunoblastic T-cell Lymphoma.**

| Patient | LDH (IU/L) | Ann Arbor Stage | PS | Extranodal sites | WBC (×10³/μL) | Hb (g/dL) | Platelet count (×10³/μL) | IgA (mg/dL) | PIAI | ATPI | Survival (months) |
|---------|------------|----------------|----|------------------|---------------|-----------|------------------------|-------------|------|-----|------------------|
| 1       | 1682H      | IVB 0           | Pleural effusion | Ascites | 35,200 | 5.5 | 28.4 | ND | H | H | 179 |
| 2       | 191        | IISB 0          | - | - | 9,400 | 9.9 | 35.8 | 528 | H | HI | 37 |
| 3       | 556H       | IISA 0          | - | - | 7,100 | 11.3 | 13.2 | 373 | H | L | 145+ |
| 4       | 226        | IISB 0          | Skin | 9,000 | 9.7 | 4.2 | 168 | H | L | 74+ |
| 5       | 264H       | IVA 0           | Pleural effusion | Hepatomegaly | 7,100 | 6.6 | 1.8 | ND | H | HI or H | 9+ |
| 6       | 315H       | IVA 0           | Skin | 7,500 | 12.9 | 30.2 | 348 | L | L | 78+ |
| 7       | 242H       | ND 0            | - | - | 6,600 | 10.2 | 14.7 | 1,292 | H | HI | ND |
| 8       | 193        | IIIA 0          | - | - | 4,900 | 14.0 | 18.5 | 554 | L | LI | 110+ |
| 9       | 198        | IVB 0-1         | - | - | 4,300 | 14.9 | 25.5 | 111 | L | L | 72+ |
| 10      | 328        | IISA 0          | Pancreas | 7,600 | 11.5 | 17.5 | 1,378 | L | HI | 93+ |
| 11      | 993H       | IVB 1           | Hepatomegaly | 8,700 | 11.2 | 0.3 | 410 | H | LI | 4 |
| 12      | 477H       | IVB 4           | Bone marrow | 19,300 | 8.4 | 4.3 | 950 | H | H | 62+ |
| 13      | 277H       | IVB 0           | Skin | 7,280 | 10.5 | 27.3 | 423 | H | HI | 45 |
| 14      | 276H       | IA 0            | - | - | 8,200 | 14.9 | 15.9 | 367 | L | L | 33+ |
| 15      | 279H       | IVB 0           | Ileum | 6,500 | 11.1 | 17.1 | 70 | H | L | 52 |

PIAI: Prognostic Index for AITL (34), ATPI: AITL prognostic index (35), L: low-risk, LI: low-intermediate-risk, HI: high-intermediate risk, H: high risk, ND: no data

**Results**

The immunohistochemical results are shown in Table 3. We first analyzed the expression of the master regulator BCL11B and the surface marker (CD3) of T-cells (Fig. 1 B, C). BCL11B was detected in 10 patients, and CD 3 was detected in all AITL patients. We then analyzed the expression of the master regulator of Th (Th-POK) and the surface markers (CD4 and CD8), naïve T-cell antigen (CD45 RA), and effector T-cell antigen (CD45RO) (Fig. 1 D-H). Th-POK was detected in 9 patients, while 7 patients showed the phenotype of the surface antigens of Th, i.e. CD4-positive and CD8-negative. All patients were positive for the effector T-cell marker (CD45RO), and all patients except two were negative for the naïve T-cell marker (CD45 RA) (14). Regarding the expression of the master regulator BCL6 and the surface antigens of TFH (CXCL13, PD-1 and SAP), BCL6, CXCL13, PD-1, and SAP were detected in 11, 8, 14, and all patients, respectively (Fig. 1 I-L).

Regarding the associations between the expression of these master regulators of T-cell differentiation and the clini-
Figure. Typical results of the immunohistochemical analysis. All of the antigens except for CD45RA and CD8 were positive. A: Hematoxylin and Eosin staining, B: BCL11B, C: CD3, D: CD45RA, E: CD45RO, F: Th-POK, G: CD4, H: CD8, I: BCL6, J: CXCL13, K: PD-1, L: SAP. A-C: Patient 15, D-H: Patient 14, I-L: Patient 2

cal characteristics shown in Table 2, the elevation of serum lactate dehydrogenase (LDH) beyond the normal upper limit was significantly associated with the BCL11B expression (p=0.0170). The patients in this study were divided into three groups based on the expression of Th-POK and BCL6, consisting of double-positive (n=5), Th-POK single-positive (n=4), and BCL6 single-positive patients (n=6). Th-POK single-positive patients showed a significantly shorter OS than the other 2 groups (median OS: 33.0 months vs. 74.0 months, p=0.020). Five of six BCL6 single-positive patients showed negativity of CD8, although this result was not statistically significant (p=0.42).

Discussion

We detected the master regulators of T (BCL11B), Th...
(Th-POK), and TFH (BCL6) cells in 10 (67%), 9 (60%), and 11 (73%) of the 15 AITL patients, respectively. Many functions of BCL11B have been reported. Physiologically, BCL11B plays critical roles in the differentiation (3, 4) and survival (22) of the T-cell lineage identity. In oncogenesis, several contradictory functions of BCL11B have been reported, such as haploinsufficient tumor suppressor effects (23) and anti-apoptosis effects (24). There have also been conflicting findings concerning the expression of BCL11B in T-cell lymphoma/leukemia. While monoallelic BCL11B deletions or missense mutations are reportedly found in 9% of T-cell acute lymphoblastic leukemia (T-ALL) (23), BCL11B mRNA expression has been reported in 36% (8/22) of T-ALL cell lines (25) and acute type adult T-cell leukemia/lymphoma (26). However, to our knowledge, there have been no previous reports concerning the BCL11B expression in AITL patients.

Th-POK and BCL6 are master regulators of Th and TFH lineage commitment, respectively (5, 8, 9), both of which belong to the poxvirus and zinc finger (POZ) and Krüppel-type (POK) protein family. POK family members often act as oncogenes in various hematological malignancies (27). For example, chromosomal translocation involving PLZF ([t(11;17) (q23;q21), PLZF] is associated with acute promyelocytic leukemia (28), and BCL11B acts as a proto-oncogene and is highly expressed in non-Hodgkin’s lymphoma (29). Furthermore, the dysregulation of Th-POK (30) and BCL6 (31) causes non-Hodgkin’s T- and B-cell lymphoma, respectively. Very few reports have examined the expression of Th-POK in lymphoma, including AITL. We previously reported that Th-POK was immunohistochemically expressed in 10 of 10 PTCL, NOS patients (13). Although Th-POK is a master regulator of CD4-positive/CD8-negative Th lineage commitment (5), our analysis showed that most (5/6) Th-POK-negative patients were also CD4-positive/CD8-negative. However, previous reports have examined the expression of BCL6 in AITL. Yuan et al. reported that extrafollicular BCL6 expression was observed in all 8 AITL patients they analyzed, with values ranging from 10% to 50% (32), and Dupuis et al. reported BCL6 expression in 16 of 21 (76%) AITL patients (16). Recently, a loss-of-function mutation in TET2 was reported to be frequent (33-83%) in AITL patients, resulting in the deregulated BCL6 expression caused by hypermethylation at intron 1 of BCL6 (33).

While CD3, a T-cell marker, was positive for all patients in our study, only 47% (7/15) of the patients featured a set of surface antigens compatible with Th (CD4-positive and CD8-negative). As for TFH markers, CXCL13, PD-1, and SAP were positive for 53% (8/15), 93% (14/15), and all (15/15) patients in our study, respectively, the corresponding values reported by other studies were 86% (25/29) (15), 100% (29/29) (16), 86% (42/49) (18), 100% (23/23) (17), and 86% (59/69) (18), respectively. The presence of a polymorphous infiltrate with reactive inflammatory cells often makes the histological diagnosis of AITL difficult. However, the detection of master regulators of T-cell differentiation in T-cell lymphomas is essential for determining their normal counterparts. An immunohistochemical analysis combining these conventional surface markers and the master regulators of T-cell differentiation may therefore improve the accuracy of the histological diagnosis of AITL.

Because BCL11B, Th-POK and BCL6 play roles not only as master regulators of T-cell differentiation but also in oncogenesis, as described above, the expression of these regulators might be associated with the pathogenesis and clinical findings of AITL. In the present study, the BCL11B expression was significantly associated with the elevation of the serum LDH level beyond its normal upper limit, and Th-POK-positive/BCL6-negative patients showed a worse OS than other patients. Two recent reports regarding the prognosis of AITL were published by the International Peripheral T-cell Project (Prognostic Index for AITL, PIAI) (34) and Japan (AITL Prognostic Index, ATPI) (35). We analyzed only a limited number of patients in the present study. Further investigations including the findings of these master regulators are needed to clarify the clinical characteristics associated with the pathophysiology of T-cell lymphoma.

The authors state that they have no Conflict of Interest (COI).

References

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, 2008.
2. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712, 1999.
3. Ikawa T, Hirose S, Masuda K, et al. An essential developmental checkpoint for production of the T cell lineage. Science 329: 93-96, 2010.
4. Li L, Leid M, Rothenberg EV. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science 329: 89-93, 2010.
5. He X, He X, Dave VP, et al. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 433: 826-833, 2005.
6. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669, 2000.
7. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for T2 cytokine gene expression in CD4 T cells. Cell 89: 578-596, 1997.
8. Nurieva RI, Chung Y, Martinez GJ, et al. Bcl6 mediates the development of T follicular helper cells. Science 325: 1001-1005, 2009.
9. Johnston RJ, Poohole AC, DiToro D, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325: 1006-1010, 2009.
10. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061, 2003.
11. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133, 2006.
12. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leu-
kaemia/lymphoma cells. Br J Haematol 126: 81-84, 2004.

13. Matsumoto Y, Horiike S, Ohshiro M, et al. Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol 133: 281-290, 2010.

14. Heyd F, ten Dam G, Möröy T. Auxiliary splice factor U2AF26 and transcription factor GIF1 cooperate directly in regulating CD45 alternative splicing. Nature Immunol 7: 859-867, 2006.

15. Gropp KL, Attygalle AD, Macon WR, Remstein ED, Kurtin PJ, Dogan A. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood 106: 1501-1502, 2005.

16. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30: 490-494, 2006.

17. Dorfman DM, Brown JA, Shalshafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 30: 802-810, 2006.

18. Roncador G, García Verdes-Montenegro JF, Tedoldi S, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 92: 1059-1066, 2007.

19. deLeval L, Rickman DS, Thielcn C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109: 4952-4963, 2007.

20. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67: 10703-10710, 2007.

21. Nagoshi H, Kuroda J, Kobayashi T, et al. Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis. Int J Hematol 89: 366-374, 2013.

22. Wakabayashi Y, Watanabe H, Inoue J, et al. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. Nat Immunol 4: 533-539, 2003.

23. Gutierrez A, Kentsis A, Sandra T, et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood 118: 4169-4173, 2011.

24. Grabarczyk P, Przybylski GK, Depke M, et al. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene 26: 3797-3810, 2007.

25. Nagel S, Kaufmann M, Drexlcr HG, MacLeod RA. The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14) (q35.1; q32.2). Cancer Res 63: 5329-5334, 2003.

26. Oshiro A, Tagawa H, Ohshima K, et al. Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 107: 4500-4507, 2006.

27. Maeda T. Regulation of hematopoietic development by ZBTB transcription factors. Int J Hematol 104: 310-323, 2016.

28. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 12: 1161-1167, 1993.

29. Maeda T, Hobbs RM, Merghoub T, et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433: 278-285, 2005.

30. Lee HO, He X, Mookerjee-Basu J, et al. Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas. Proc Natl Acad Sci U S A 112: 7773-7778, 2015.

31. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262: 747-750, 1993.

32. Yuan CM, Vergilio JA, Zhao XF, Smith TK, Harris NL, Bagg A. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum Pathol 36: 784-791, 2005.

33. Nishizawa S, Sakata-Yanagimoto M, Hattori K, et al. BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. Int J Hematol 105: 465-469, 2017.

34. Federico M, Rudiger T, Ballei M, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol 31: 240-246, 2013.

35. Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119: 2837-2843, 2012.